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ABSTRACT
Objectives: To evaluate the long-term cost-
effectiveness of collaborative care (vs usual care) for
treating depression in patients with diabetes and/or
coronary heart disease (CHD).
Setting: 36 primary care general practices in North
West England.
Participants: 387 participants completed baseline
assessment (collaborative care: 191; usual care: 196)
and full or partial 4-month follow-up data were
captured for 350 (collaborative care: 170; usual care:
180). 62% of participants were male, 14% were non-
white. Participants were aged ≥18 years, listed on a
Quality and Outcomes Framework register for CHD
and/or type 1 or 2 diabetes mellitus, with persistent
depressive symptoms. Patients with psychosis or
type I/II bipolar disorder, actively suicidal, in receipt
of services for substance misuse, or already in
receipt of psychological therapy for depression were
excluded.
Intervention: Collaborative care consisted of
evidence-based low-intensity psychological
treatments, delivered over 3 months and case
management by a practice nurse and a Psychological
Well Being Practitioner.
Outcome measures: As planned, the primary
measure of cost-effectiveness was the incremental
cost-effectiveness ratio (cost per quality-adjusted life
year (QALY)). A Markov model was constructed to
extrapolate the trial results from short-term to long-
term (24 months).
Results: The mean cost per participant of collaborative
care was £317 (95% CI 284 to 350). Over 24 months, it
was estimated that collaborative care was associated
with greater healthcare usage costs (net cost £674
(95% CI −30 953 to 38 853)) and QALYs (net QALY
gain 0.04 (95% CI −0.46 to 0.54)) than usual care,
resulting in a cost per QALY gained of £16 123, and a
likelihood of being cost-effective of 0.54 (willingness to
pay threshold of £20 000).
Conclusions: Collaborative care is a potentially cost-
effective long-term treatment for depression in patients
with comorbid physical and mental illness. The
estimated cost per QALY gained was below the
threshold recommended by English decision-makers.
Further, long-term primary research is needed to
address uncertainty associated with estimates of
cost-effectiveness.
Trial registration number: ISRCTN80309252;
Post-results.
Strengths and limitations of this study
▪ COINCIDE was a large randomised controlled
trial (RCT) of a pragmatic intervention with good
retention rates.
▪ Bias and confounding were minimised using a
variety of methods at all stages from study
design and recruitment to data analysis.
▪ There was a notable proportion of missing data;
multiple imputation of missing values was used
to minimise bias.
▪ The conclusions reported about the long-term
cost-effectiveness of collaborative care are extra-
polated from a short-term (4-month) RCT and
therefore subject to uncertainty; structural and
parameter uncertainty in the economic model
were explored in sensitivity analyses.
▪ The economic model and sensitivity analyses
demonstrated good external validity with findings
from meta-analyses (clinical effectiveness) and
narrative systematic reviews (cost-effectiveness)
and results were not sensitive to alternative mod-
elling assumptions.
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INTRODUCTION
Major depression is a common disabling condition esti-
mated to affect 3% of the English general population;1
the prevalence and burden in individuals with long-term
physical conditions (such as diabetes or heart disease) is
higher still.2–6 Factors associated with depression, such
as poor self-care, can lead to complications and higher
mortality from physical health conditions.7 8 In time-
restricted and performance-managed primary care set-
tings, detecting and diagnosing depression in people
with long-term conditions can be especially problematic.
Patients and healthcare professionals commonly dismiss
depression as an inevitable consequence of long-term
conditions and favour strategies that prioritise physical
health.9–12
Global and English health policy has recognised the
importance of improving mental health generally and
speciﬁcally among those with physical health pro-
blems.13 14 In England, government policy has increas-
ingly promoted increased access to mental healthcare
through commissioning and provision of health and
social care in the primary care setting. This is supported
by the Improving Access to Psychological Therapies
(IAPT) initiative. It is important to explore ways in
which the IAPT initiative can be capitalised on to
improve healthcare and health outcomes for patients.
Collaborative care is a complex intervention which may
provide a framework for delivering IAPT-based treat-
ments. Collaborative care was developed in the USA and
involves the use of a case manager working with primary
care professionals, often supervised by a mental health
specialist and supported by appropriate care manage-
ment systems that can enhance interprofessional com-
munication and facilitate proactive and scheduled
follow-up of patients.15–17
A deﬁnitive Cochrane review reported that collabora-
tive care effectively treated depression and anxiety over
the short (0–6 months), medium (7–12 months) and
long term (13–24 months), compared with usual care.18
The review deﬁned usual care as one of: no additional
intervention; the same additional intervention applied to
both study arms (effects potentially cancelled out); or
enhanced usual care (a non-collaborative intervention
that the collaborative care arm did not receive). Much of
the evidence is drawn from the USA, where care is orga-
nised, provided and funded differently from the UK.
However, the COINCIDE and CADET trials showed that
the short-term and medium-term beneﬁts of collaborative
care also translate to the English healthcare system.15 19
There is good evidence (from the USA) that collaborative
care is also effective for treating depression in people
with coexisting long-term physical health conditions.20–23
Evidence that collaborative care is cost-effective is more
limited, and again mostly from the USA.24 25 However,
an economic evaluation of CADET has recently shown
that compared with usual care, collaborative care is cost-
effective in the medium term (12 months), from the
perspective of the English National Health Service
(NHS).26 Analysis of complete-case data in that trial, esti-
mated that collaborative care offered a mean incremental
gain of 0.02 (95% CI –0.02 to 0.06) quality-adjusted life
years (QALYs) over 12 months, at a mean incremental
cost of £270.72 (95% CI –202.98 to 886.04). This resulted
in a cost per QALY of £14 248 and a probability of 0.58
that collaborative care was cost-effective if decision-makers
are willing to pay £20 000/QALY gained.
The long-term (>12 months) clinical and cost-
effectiveness of collaborative care in the English health-
care system have not been evaluated previously. The
long-term effectiveness of collaborative care may be par-
ticularly relevant to patients with comorbid physical ill-
nesses if an artefact of collaborative care is an altered
trajectory of mental and/or physical health needs or
long-term improvements in relationships with healthcare
practitioners/self-care.20 27 A trial of a collaborative care
for managing depression in patients with cancer
reported a higher cost per QALY gained over 5 years
than over 20 years, suggesting it may become better
value with an increasing time horizon.28
The COINCIDE trial was a robust, pragmatic rando-
mised controlled trial (RCT) of collaborative care versus
usual care, delivered in routine primary care in the
English NHS to trial participants with a long-term condi-
tion (diabetes and/or coronary heart disease (CHD))
and depression.16 Owing to logistical constraints,
COINCIDE participants were only followed for 4
months.17 CHD and diabetes are lifelong conditions,
and depression can be a recurrent, chronic condition.
Therefore, it is important to consider the effectiveness
of collaborative care in this population over long-term
periods. Economic models can be used to extrapolate
the cost-effectiveness ﬁndings from a short-term RCT to
longer time horizons and alternative settings and
populations.29
This study is important because it makes a robust con-
tribution to economic evidence about estimated costs
and beneﬁts of implementing collaborative care in the
English healthcare system (NHS England). Existing evi-
dence is limited to studies conducted in the US health-
care system which may not be relevant to the
implementation of collaborative care in the NHS.
Emerging evidence from a single English complete-case
analysis suggests that collaborative care may be cost-
effective in this context over 12 months. However, it is still
unknown whether these ﬁndings are likely to translate to
longer time horizons. This analysis uses an economic
model to estimate the cost-effectiveness of collaborative
care in the context of the NHS at 12, 24 and 36 months.
This has not been done previously. Furthermore, this is
the ﬁrst analysis of the cost-effectiveness of collaborative
care in the NHS for patients with long-term physical con-
ditions alongside depression (multimorbidity).
Aim: To use an economic model to extrapolate trial-
based cost-effectiveness estimates for collaborative care
versus usual care over a long-term (24 months) time
horizon. The key objectives were to:
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▸ Develop an economic model to represent the key
health states and events observed during the
COINCIDE trial of collaborative versus usual care;
▸ Estimate the costs of health and social care in the col-
laborative care and usual care groups;
▸ Assess whether there are differences in costs between
collaborative care and usual care;
▸ Estimate the health status and QALYs of patients in
the collaborative care and usual care groups;
▸ Assess whether there are differences in health status
and QALYs between collaborative care and usual care;
▸ Estimate the long-term cost-effectiveness of collabora-
tive care, compared with usual care.
METHODS
Randomised controlled trial
The COINCIDE trial was an integrated clinical and eco-
nomic study to evaluate the effectiveness and cost-
effectiveness of a collaborative care intervention in
people with diabetes and/or CHD who had comorbid
depression. The evaluation was a cluster RCT of 36
primary care (general) practices in the North West of
England, randomised to provide either collaborative
care or usual care. Randomisation was by a central
service, separated from the investigators, using minimisa-
tion based on practice size and deprivation. Three
hundred and eighty-seven participants were recruited;
191 at practices randomised to deliver collaborative care
and 196 at practices delivering usual care. Sixty-two per
cent of participants were male, 14% were of non-white
ethnicity. The majority (76%) of participants were from
moderately/highly deprived areas (54% from highly
deprived areas) and had a mean of 6.2 (SD 3.0) medical
conditions in addition to diabetes and/or CHD. Full
details of the trial design are reported elsewhere.16 17
practices were eligible for inclusion if they held and
maintained a Quality Outcomes Framework (QOF)
register of patients with CHD and diabetes mellitus.30
Patients aged ≥18 years attending each practice were eli-
gible for inclusion if they were listed on either of these
QOF registers and had persistent depressive symptoms
(≥10 on Patient Health Questionniare-9 (PHQ-9)).31
Participants attending practices in the collaborative
care arm were offered a choice of appropriate evidence-
based low-intensity psychological treatments, delivered
over 3 months through IAPT services. Case management
was provided jointly by the practice nurse and a
Psychological Well Being Practitioner (PWP; graduate
psychologists employed by IAPT to provide high-volume,
low-intensity psychological interventions).
Participants attending practices allocated to usual care
received standard management from their primary care
team. Standard management for depression in adults
with physical health conditions can vary but should
include the components of the National Institute for
Health and Care Excellence (NICE) stepped care model
which includes support from general practitioners
(GPs), referral for a range of low-intensity to high-
intensity psychological interventions and/or antidepres-
sant therapy (dependent on severity of depression,
patient preference and prior experience).32 In line with
the pragmatic nature of this evaluation, patients in the
usual care group could receive antidepressant treatment
and referral for psychological therapy, although this was
not delivered by a specially trained COINCIDE PWP.
The primary clinical outcome was the difference
between the collaborative and usual care groups in the
mean score on the 13 depression-related items of the
90-item symptom checklist (SCL-D13)33 at the end of a
4-month follow-up period. This was collected at follow-up
for 170 participants in the collaborative care group and
180 in the usual care group. Participants in the collabora-
tive care arm had a lower mean SCL-D13 depression
score (difference −0.23; 95% CI −0.41 to −0.05; adjusted
standardised effect size 0.30) and also reported being
better self-managers, rated their care as more patient
centred and were more satisﬁed with their care.19
Economic evaluation
Measuring health benefit
The primary measure of health beneﬁt for the analysis
was the QALY, estimated from the EuroQol ﬁve dimen-
sion questionnaire, 5-level version (EQ -5D-5L) and asso-
ciated utility tariffs.34 35 The EQ-5D is a validated,
generic, preference-based measure of health status,
widely used in national health surveys in the UK and clin-
ical trials of mental health interventions. The EQ-5D is
currently recommended for by the NICE to estimate
health state utility weights for the calculation of QALYs.36
QALYs are estimated as the average time spent in a
health state multiplied by the average utility weight asso-
ciated with it. Despite being a global measure, a system-
atic review reported that the EQ-5D demonstrates good
construct validity and is sensitive to changes in depres-
sion.37 In COINCIDE, there were signiﬁcant relationships
between baseline utility values and clinical outcome mea-
sures (SCL-90, Pearson −0.311, p≤0.001; PHQ-9, Pearson
−0.307, p≤0.001; World Health Organisation-Quality of
Life instrument (WHO-QOL), Pearson 0.448, p≤0.001;
generalised anxiety disorder assessment, 7-item version
(GAD-7), Pearson −0.231, p≤0.001; Symptom Disruption
Score (SDS), Pearson −0.384, p≤0.001; burden of dis-
eases, Pearson −0.454, p≤0.001).
Measuring costs
Data on the resources used to establish and deliver the
intervention were collected from activity logs completed
by the PWPs and practice nurses delivering collaborative
care. In addition to the main and collaborative sessions,
this also included note writing and supervisions attended
by the PWPs. The costs of training were also included in
the primary analysis. Data on the use of other health and
social care services were collected by questionnaire com-
pleted by participants at initial (4-month) follow-up. The
services included primary and community care, hospital
Camacho EM, et al. BMJ Open 2016;6:e012514. doi:10.1136/bmjopen-2016-012514 3
Open Access
group.bmj.com on October 19, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
inpatient and outpatient care, prescribed medications,
and patient health-related costs and expenses (travel to
healthcare appointments and private medical expenses
exceeding £50, eg, reﬂexology). The costs of resources
used were estimated as the product of the resource use
and its unit cost. The unit costs of the services used were
originally derived from the 2011–2012 Reference Costs
database (published by the Department of Health),
2011–2012 unit costs of primary and community health
and social care services (published by the Personal and
Social Services Research Unit), and the 2011–2012
British National Formulary (BNF) handbook38–40 (see
online supplementary table S1). All costs were inﬂated to
2014/2015 prices, based on the Hospital and
Community Health Services (HCHS) Index.38
Participants were also asked about support from family
and friends. However, a high level of missing data and
inconsistency of reporting meant that it was not possible
to estimate reliable costs for this resource.
Missing data
Missing data on costs and EQ-5D domains were imputed
using the multiple imputation chained-equation proced-
ure, which is robust against assumptions that data are
missing not at random. The multiple imputation proced-
ure included baseline covariates identiﬁed as predictors
of costs and utilities (EQ-5D pain/discomfort, number
of additional conditions, Bayliss burden of disease score,
PHQ-9 score, SDS, social or family life, ethnicity, employ-
ment, GP practice) in addition to age, sex and baseline
SCL-D13 score.
Economic model
Both the primary and sensitivity analyses used the frame-
work of cost-effectiveness and cost-effectiveness acceptabil-
ity analysis to evaluate the potential for collaborative care
to be cost-effective in an NHS primary care setting. The
perspective for the evaluation was that of the patient
(health beneﬁts) and health and social care services
(costs)—an approximation of the societal perspective.
The target population for the economic model analyses
was people with diabetes and/or CHD with comorbid
depression. Data from participants in COINCIDE were
used to represent this population. Differences between
model parameters estimated from COINCIDE data and
results reported from other published evaluations were
explored in sensitivity analyses (described below).
The time horizon for the primary analysis was
24 months. An annual discount rate of 3.5% was applied
to costs and effects for the period beyond 12 months, as
per NICE recommendations for economic evaluations in
healthcare.36 The simulation software was TreeAge Pro
plus Healthcare. The primary measure of cost-effective-
ness for the model analyses was the incremental cost-
effectiveness ratio (ICER), reported as cost per QALY
gained from collaborative care. This was calculated as:
Costsðcollaborative careusual careÞ=QALYsðcollaborative careusual careÞ
Model structure
A simple economic model that combined a decision tree
and a Markov cohort model was constructed (ﬁgure 1).
The initial decision tree structure was based on the care
pathways and outcomes observed over 4 months in
COINCIDE. Decision trees are simple and transparent,
clarifying the options of interest. The distribution of par-
ticipants in terms of allocation to collaborative/usual
care and subsequent depression status (SCL-D13<20 not
depressed; SCL-D13≥20 depressed41) at the end of the
initial follow-up period were described in the model.
A Markov cohort model was constructed for each
study arm to extrapolate the ﬁndings from COINCIDE
over a long-term time horizon. Markov models handle
both costs and outcomes intuitively which makes them a
powerful tool in economic evaluation.42 They are par-
ticularly useful for modelling chronic conditions with
ﬂuctuating severity, such as depression, over time. The
24-month time horizon was split into ﬁve cycles of
4 months to reﬂect the transition between depression
states observed during the trial. The health states repre-
sented in the model were based on the observed out-
comes from COINCIDE: depressed, not depressed,
dead. The distribution of participants across the health
states at the start of the model was different between the
study arms, reﬂecting the observed proportion of partici-
pants in each health state at the end of the initial
4-month follow-up. The health states and possible transi-
tions between them were the same for both models.
Probability of events
The probabilities of following the different pathways
through the decision tree or moving between the health
states in the Markov model were derived from
COINCIDE. The proportion of participants in each
health state at the end of the initial follow-up was used
to estimate the probability of transitioning between
health states for the model. All participants recruited to
COINCIDE were identiﬁed as depressed; this was based
on a PHQ-9 score ≥10. There was a proportion of parti-
cipants in both study arms who did not have a baseline
SCL-D13 score ≥20; the estimated probability of becom-
ing depressed was derived from the outcomes of these
participants during the trial. Three participants died
before outcome data had been collected at the initial
4-month follow-up, both of whom had SCL-D13 scores
≥20 (ie, classiﬁed as depressed in this model). This was
applied to the primary analysis as depression-related
mortality rate of 0.02 over 4 months. Cardiovascular
events were not accounted for in the model as data were
not available to explore whether/how the intervention
was associated with their likelihood and long-term
impact on health status.
Modelling resource use, costs and QALYs
The mean cost and SE of resource use (including direct
costs of the collaborative care intervention) and utility
weights observed in the trial were used to generate point
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estimates associated with the different health states in
the model. Estimates were produced separately for each
intervention group.
The event probability, cost and utility parameters are
summarised in table 1. In the primary model, it was
assumed that the impact of collaborative care on the
utilities associated with each health state and the likeli-
hood of moving between the health states was not sus-
tained beyond the initial 4-month follow-up; utilities and
event probabilities were the same in both models. This
assumption was explored in one-way sensitivity analyses
(described below).
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA) was used to assess
the level of parameter uncertainty (from uncertainty/
variance in the data inputs). Each model parameter
(event probability, cost or QALY) was assigned a primary
value (mean base on data observed from COINCIDE)
and a distribution of possible values (see table 1). Monte
Carlo simulation was used to estimate mean expected
costs and outcomes, and statistical measures of expected
variance (SD) around the mean for each of 10 000 itera-
tions drawn from the distributions deﬁned. Each of the
10 000 net outcome estimates were revalued by a willing-
ness to pay threshold (WTPT) of £20 000 (current NICE
decision threshold).36 This was repeated for each of a
range of WTPTs. A cost-effectiveness acceptability curve
(CEAC) was plotted to show the proportion of boot-
strapped simulations where the net beneﬁt of collabora-
tive care was greater than zero for each WTPT.43–46
One-way sensitivity analyses
Methodological uncertainty (from the model structure,
selection of data inputs or other assumptions) was
addressed by one-way sensitivity analysis. For each
one-way sensitivity analysis, the parameter of interest was
set to a speciﬁc value and the PSA and cost-effectiveness
acceptability analyses rerun, to assess the robustness of
the results to changes in that variable. Parameter values
for sensitivity analyses were chosen either as systematic
variations around the values in the primary model or
from differences between observed data from
COINCIDE and CADET and published meta-analyses
(clinical effectiveness) and narrative systematic reviews
(cost-effectiveness). The parameters tested by one-way
sensitivity analysis included time horizon, effectiveness
of collaborative care, discount rate for costs and QALYs,
mortality rate, and intervention costs.
RESULTS
Within-trial analysis
The probability of being depressed (SCL-D13≥20)41 at
the end of the initial 4-month follow-up was lower for
Figure 1 Decision tree and
Markov model.
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participants randomised to collaborative care (0.57,
95% CI 0.50 to 0.65) than usual care (0.72, 95% CI
0.66 to 0.78; p=0.004; imputed data). The mean cost
per participant of delivering the collaborative care
intervention (including training/supervision/set-up
costs) was £317 (£168—when training costs were
excluded). The mean (unadjusted) costs of health ser-
vices used during the trial period was higher for the
collaborative care group (£1896, 95% CI 1468 to 2224)
than usual care (£1515, 95% CI 1205 to 1826); this
included the cost of delivering the intervention and
the cost of health services used. Use of health services
is summarised by study arm in online supplementary
table S1. The mean number of QALYs gained by parti-
cipants randomised to collaborative care (0.185, 95%
CI 0.064 to 0.303) was also higher than usual care
(0.169, 95% CI 0.017 to 0.323). Although the mean
costs and QALYs were higher for participants rando-
mised to receive collaborative care, compared with
usual care, the 95% CIs overlapped substantially, sug-
gesting that these differences were not signiﬁcant.
Within the collaborative care arm, regardless of
whether or not participants were depressed at
follow-up, the mean QALYs were greater than for the
usual care arm (depressed—mean QALYs: collaborative
care (0.168); usual care (0.158); non-depressed—mean
QALYs: collaborative care (0.207); usual care (0.196)).
The ICER for the within-trial model was £29 132/QALY
gained from collaborative care with a probability of
0.49 of being cost-effective at a WTPT of £20 000.
Economic model
Table 2 reports the mean costs and QALYs for the inter-
vention groups which were used to calculate the ICER.
The estimated cost per QALY gained from collaborative
care over a 24-month time horizon (primary analysis)
was £16 123. The uncertainty around this estimate is illu-
strated in ﬁgure 2 (represented by the spread of points
on the cost-effectiveness plane) and ﬁgure 3 (CEAC).
The probability that collaborative care is cost-effective
(vs usual care) was 0.53 at a WTPT of £20 000 and 0.60
at a WTPT of £60 000 (ﬁgure 3). The probability that
collaborative care was cost-effective fell below 0.5 at a
WTPT of £7000.
Sensitivity analyses
Table 2 presents the results of sensitivity analyses of
model assumptions. The results were not sensitive to
alternative assumptions about: time horizon, training
costs, the beneﬁts of collaborative care over time, mortal-
ity rates or discount rates. The ICER changed as
expected in response to these assumptions, ranging
from £2103 to £22 843 per QALY/gained (over
24 months) with a probability of being cost-effective
between 0.52 and 0.65.
Table 1 Model parameters for the decision tree and Markov model
Mean SE Distribution
Probabilities*
Within trial—likelihood of being depressed at follow-up: usual care 0.72 0.030 Triangular 0.72±20%
Within trial—likelihood of being depressed at follow-up: collaborative care 0.57 0.039 Triangular 0.57±20%
Markov transition: not depressed→depressed 0.37 − Triangular 0.37±20%
Markov transition: remains depressed 0.71 − Triangular 0.71±20%
Markov transition: depressed→dead 0.02 − Triangular 0.02±20%
Markov transition: not depressed→dead† 0 − −
Costs
Within trial: usual care 1670 203 γ
Within trial: collaborative care 2140 264 γ
Markov state: not depressed 1516 257 γ
Markov state: depressed 1730 219 γ
Markov state: dead 0 − −
QALYs
Within trial: usual care 0.169 0.006 β
Within trial: collaborative care 0.185 0.007 β
Markov state: not depressed (usual care) 0.196 0.008 β
Markov state: depressed (usual care) 0.158 0.007 β
Parameters for sensitivity analyses‡
Markov transition: not depressed→depressed (collaborative care) 0.19 − Triangular 0.19±20%
Markov transition: remains depressed (collaborative care) 0.56 − Triangular 0.56±20%
Markov state: not depressed (collaborative care) 0.207 0.005 β
Markov state: depressed (collaborative care) 0.168 0.007 β
*Probabilities not stated in the table are the exhaustive compliment of reported probabilities for each model event.
†Background all-cause mortality assumed to be 0.
‡Primary analysis assumed equivalent probabilities/utilities (usual care) for both trial groups.
QALY, quality-adjusted life year.
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Subgroup analyses
The model parameters used in subgroup analyses are
reported in online supplementary table S2. The para-
meters were derived from the COINCIDE trial which
was not powered for subgroup analyses. As such these
parameters are more uncertain than for the whole
sample and so results should be interpreted with
caution. Online supplementary table S3 presents the
results of subgroup analyses on the basis of age at base-
line and number of physical conditions reported (in
addition to diabetes/CHD). Based on the mean age of
the sample (58 years), and the (former) age of retire-
ment for women in England (60 years), two subgroups
were deﬁned: under 60 and 60+ years. There was little
difference in the likelihood that collaborative care is
cost-effective in participants under 60 years old (ICER
£16 891; probability cost-effective (£20k/QALY) 0.49) or
those older than 60 (ICER £23 358; probability cost-
effective (£20k/QALY) 0.49), despite a lower ICER for
the under 60 group. This reﬂects the additional uncer-
tainty around these subgroup estimates. Based on the
mean number of long-term conditions reported (other
than diabetes or CHD), two subgroups were deﬁned:
fewer than 6 conditions and 6+ conditions. Collaborative
care may be less likely to be cost-effective in participants
with more than six additional conditions (ICER £33 210;
probability cost-effective (£20k/QALY) 0.50), compared
to those with fewer than six (ICER £9625; probability
cost-effective (£20k/QALY) 0.55).
DISCUSSION
Principal findings
The results described here suggest that over a 24-month
time horizon, collaborative care, for patients with
depression plus comorbid cardiovascular disease and/or
diabetes, is potentially cost-effective compared with
usual care in the English healthcare system.
Comparison with other studies
The relative risk of depression for usual versus collabora-
tive care observed in COINCIDE was the same as esti-
mated from a meta-analysis of RCTs over a range of
follow-up periods up to 24 months.18 Comparison of the
ICERs estimated from this model at 12, 24 and
36 months support the ﬁnding that collaborative care is
better value over longer time horizons.28 Economic
evaluation of the medium-term (12 month) effects of
collaborative care in the English healthcare system
reported from CADET was similar to the 12-month
results from our model.26 The QALYs gained from col-
laborative care over 12 months (CADET 0.02;
COINCIDE 0.03) and probability of cost-effectiveness at
a WTPT of £20 000 (CADET 0.58; COINCIDE 0.53)
were comparable. The estimated cost of delivering col-
laborative care (CADET £273; COINCIDE £317) and net
cost of health service resources used were higher in
COINCIDE (CADET £271; COINCIDE £560). This
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suggests that for COINCIDE participants, collaborative
care was associated with an impact on health service
usage. This may result from improved self-care/manage-
ment of physical health conditions.20 27 This also reﬂects
the speciﬁc impact of implementing collaborative care in
patients with complex needs arising from multimorbidity
and highlights the importance of examining this group as
a special case. The mean QALY gain from collaborative
care over 18–24 months reported in a systematic review24
was the same as when it was assumed that the beneﬁt of
collaborative care observed during COINCIDE waned by
10% every 4 months. Even when it was assumed that the
beneﬁcial effect of collaborative care increased by 25%
every 4 months, the estimated QALY gain over 24 months
(0.21) did not reach the level estimated by a seemingly
comparable US study (0.34).25 This exempliﬁes the difﬁ-
culty of generalising between studies and the need for
health service-speciﬁc research.
Strengths and limitations
The parameters used in the decision model were
derived from within-trial data and so are subject to the
Figure 2 Incremental
cost-effectiveness, collaborative
care versus usual care. QALY,
quality-adjusted life year.
Figure 3 Cost-effectiveness
acceptability curve. QALY,
quality-adjusted life year.
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same strengths and limitations as the trial.19 COINCIDE
was a large pragmatic trial (integrated within routine
NHS settings) with good retention rates. A range of
recruitment (eg, from diverse geographical/sociodemo-
graphic areas), randomisation (eg, cluster randomisation
of practices) and analytic (eg, multiple imputation;
adjusting for baseline characteristics) techniques were
used to minimise bias and confounding and so ensure
that the results of the economic evaluation are also
likely to be robust and representative of routine practice.
Data regarding the usage of healthcare during the
study period were self-reported by participants, collected
via questionnaire at follow-up assessment. Participants
may not be able to accurately recall each time they used
a healthcare service, or may be unclear which category
different services come under. These issues may affect
people who use a large amount of healthcare services
more. Veriﬁcation against medical records may increase
the reliability of these data; however, access to medical
records was not agreed for COINCIDE participants.
There were 210 (54%) participants with complete
EQ-5D (utility), healthcare usage (cost) and baseline
covariate data. Multiple imputation of missing data for
all COINCIDE participants reduced the potential for
bias associated with missing data. However, the robust-
ness of any imputation method declines as the level of
missing data increases, reducing the validity and reliabil-
ity of the analyses. For example, the high level of
missing data and inconsistency of reporting for informal
care received (from friends and family) meant that it
was not possible to reliably impute data. The estimated
cost-effectiveness may have been sensitive to the inclu-
sion of informal care costs, but it is not possible to know
the magnitude or direction of any effect. Findings
reported here about the cost-effectiveness of collabora-
tive care over 24 months (used to denote long-term
follow-up in comparable trials of collaborative care18)
were estimated from an extrapolation of short-term
(4-month) trial data. The physical health conditions
experienced by the cohort are long term and depression
can also be a chronic, recurrent condition. The cost-
effectiveness of collaborative care over 36 months (very
long term) was explored in sensitivity analyses, but in
this population, longer horizons (eg, 5–10 years) may
also be important. There is already uncertainty around
the ICERs estimated for 24 months. Extending the time
horizon for this model would stretch the evidence from
the trial too far (limiting robustness and increasing
uncertainty). The economic model presented here
demonstrated good external validity; results are sup-
ported by ﬁndings from other trials/reviews and the
ICER changed as expected in response to the different
one-way sensitivity analyses. Furthermore, the conclusion
regarding cost-effectiveness and the probability that
collaborative care is cost-effective did not vary greatly
across sensitivity or subgroup analyses. This indicates
that the model is robust. However, the probability of
cost-effectiveness was conservative, even for an ICER of
<£4000/QALY. This is due to differing levels of uncer-
tainty around the estimates of costs and QALYs which
can be seen by comparing the width of 95% CIs around
the means (table 2 and see online supplementary
table S3).
In a US study, collaborative care was associated with
better self-management of diabetes and/or CHD.20
There may be an important long-term impact of
improved self-management on mortality (or other long-
term health outcomes), especially among patients with
multimorbidities. It was not possible to ascertain the
long-term effect of collaborative care on morbidity and
mortality for COINCIDE participants and so this was not
explored further here.
CONCLUSION
These ﬁndings contribute to the evidence base in
support of the commissioning of collaborative care for
patients with depression in England. For the ﬁrst time, it
has been demonstrated that collaborative care may also
be cost-effective in the English health service for patient
groups with depression in conjunction with long-term
physical health conditions, and over a long-term time
horizon. However, the long-term ﬁndings were extrapo-
lated from 4-month trial data and so associated with some
uncertainty. Collection of long-term and very long-term
clinical and cost-effectiveness data from a pragmatic RCT
of collaborative care for patients with multimorbidities,
which can be included in an updated meta-analysis, is
needed to address this uncertainty.
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